Who Actually Benefits from Classifying Obesity as a Disease?

Max Moser posits that framing obesity as a disease primarily benefits GLP-1 drug makers, drawing parallels to the antidepressant boom. This opinion piece questions the motivations behind the medicalization of obesity, suggesting financial incentives from pharmaceutical companies like Eli Lilly and Novo Nordisk. It asks whether this classification genuinely serves public health or primarily boosts drug sales.